Ceribell, Inc. · NASDAQ:CBLL
Ceribell — Q2 2026 Earnings Presentation
33 slides from Ceribell's earnings presentation, Aug 10, 2026
Slide 1: Corporate Presentation
Corporate Presentation August 2026
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about the Company and its industry. These statements and the outcomes of the events they describe involve substantial risks, uncertainties and potentially in
Slide 3: AI-Powered Point-of-Care EEG Platform Targeting Serious Neurological Conditions
AI-Powered Point-of-Care EEG Platform Targeting Serious Neurological Conditions in the Acute Care Setting 3
Slide 4: Large & Expanding Potential Market Opportunity
Large & Expanding Potential Market Opportunity1 Financial Highlights U.S. only $3.5B $114M – $117M FY 2026 Guidance2 Delirium >$2B Pediatric & Neonate Seizure Acute Care 33% Q2 2026 YoY Revenue Growth3 Adult Seizure Adult Seizure Acute Care Market Acute Care Market Prior TAM With Recently 90% Expand
Slide 5: Ceribell's Three Growth Horizons
Ceribell’s Three Growth Horizons LONGER TERM NEAR TERM Develop Solutions for Use Beyond the NOW Make EEG a New Vital Sign Acute Care Setting In Acute Care New Clinical Settings Seizure Detection Indication Expansion in ICU in the Acute Care Setting and ED (Delirium, LVO Stroke) Biomarkers for Non-Ac
Slide 6: Targeting Seizures in the Acute Care Setting
Targeting Seizures in the Acute Care Setting Epileptic Seizures Seizures in Acute Care (ICU & ED) Visible Non-Convulsive Time-Limited Prolonged Non-Life Threatening Life-Threatening 6
Slide 7: Seizures Are Highly Prevalent in Critically-Ill Patients and Often Go Undiagnosed
Seizures Are Highly Prevalent in Critically-Ill Patients and Often Go Undiagnosed Patient Population Estimated Prevalence of Seizures1 Following Convulsive Status Epilepticus (SE) 48% Hypoxic-Ischemic Encephalopathy Post Cardiac Arrest 10-59% Sepsis-Associated Encephalopathy 32% 92% Brain Tumors 23-
Slide 8: "Time is Brain"
"Time is Brain" STATUS EPILEPTICUS PATIENT RESPONSE RATE TO ALL-CAUSE MORBIDITY & MORTALITY RATE1 FIRST-LINE TREATMENT2 80% 75% 15% 61% Morbidity 50% Mortality 50% 40% 85% 30% 33% 10% <10 hr 10-20 hr >20 hr <0.5 <1.0 <1.5 <2.0 ≥2.0 >2.0 DURATION OF SEIZURE (Hrs) TREATMENT DELAY (Hrs) 1. Young, G.B.,
Slide 9: Guidelines and Recommendations Include Timely EEG to Detect and Manage Seizures
Guidelines and Recommendations Include Timely EEG to Detect and Manage Seizures Across Different Disease States EEG should be initiated within 15-60 minutes to “evaluate for NCSE if [patient is] not 2012 waking up after clinically obvious seizures cease.”1 “Recommend promptly performing and interpre
Slide 10: Conventional EEG Has Significant Limitations in the Acute Care Setting
Conventional EEG Has Significant Limitations in the Acute Care Setting Overview of EEG Conventional EEG systems were not designed for the acute care setting Hardware & Access Challenges An EEG is a non-invasive tool used to measure and display electrical activity in the brain Requires EEG Technician
Slide 11: Clinical Reality: Conventional EEG is Not Suited for the Acute Care Setting
Clinical Reality: Conventional EEG is Not Suited for the Acute Care Setting and Leads to Long Delays 2 1 3 EEG Arrival & Set-Up Seizure Suspicion / EEG Order EEG Interpretation Continuous Review of EEG Hours or Days1,2,3 Records is Rare4 1. Gururangan, K., et al. (2016) Clinical Neurophysiology. 127
Slide 12: Ceribell EEG System: Suspicion to Diagnosis in Minutes
Ceribell EEG System: Suspicion to Diagnosis in Minutes, Enabling Earlier & More Accurate Treatment The System Seizure Suspicion / EEG Arrival & 1 2 3 EEG Interpretation EEG Order Set-Up ~5 Minutes to Set Up1 Early detection Continuous monitoring By any trained, non-specialized healthcare professiona
Slide 13: The System
The System Combining highly portable, simple-to-use and rapidly deployable hardware with AI-powered algorithms Ceribell EEG Portal Ceribell EEG Headband AI-powered Seizure Detection Ceribell EEG Recorder Algorithm 13
Slide 14: Clarity: Our Proprietary AI-Powered Seizure Detection Algorithm
Clarity: Our Proprietary AI-Powered Seizure Detection Algorithm Bedside Alert Real-time feedback on response to medication Provides seizure burden to facilitate EEG reading for neurologists 14 Ceribell Indications CAUTION: Device does not substitute for EEG review by a qualified clinician. Before
Slide 15: Ceribell Supports Precise Patient Care for Status Epilepticus
Ceribell Supports Precise Patient Care for Status Epilepticus: Expediting Diagnosis and Continuously Monitoring Seizure Burden 15 CAUTION: Device does not substitute for EEG review by a qualified clinician. Before use, review the manual for indications, contraindications, warnings, precautions, pote
Slide 16: Validated Cost Savings Peer-Reviewed Publications & Abstracts
Validated Cost Savings 51 Peer-Reviewed Publications & 107 Abstracts* Reduced 40% 43% 53% Over-administration of changed diagnostic of patients with reduced ASM7 + changed clinical management 51% potential reduction in Anti-Seizure Medication (ASM)1 suspicion and 20% changed treatment decisions5 int
Slide 17: Evidence-Based Clinical & Economic Benefits
Evidence-Based Clinical & Economic Benefits Study Findings SAFER Study Overview The Seizure Assessment and convEEG Ceribell Forecasting with Efficient Rapid- Outcome ∆ Delta P- Value (N = 62) (N = 62)2 EEG (SAFER-EEG) study is a multisite retrospective study of Median door-to-EEG 25.3 5.9 19.4 hours
Slide 18: New for 2026: Pediatric & Neonate Indication Expansion & Commercial Launch
New for 2026: Pediatric & Neonate Indication Expansion & Commercial Launch • Received FDA clearances for Clarity algorithms for age 1+ and neonate, including pre-term in 2025 • Unlocked incremental $400M market opportunity1, including ~280 children's hospitals targets • Initiated commercial launch i
Slide 19: Seizures in Critically Ill Neonates are Common, Requiring EEG for Accurate Diagnosis
Seizures in Critically Ill Neonates are Common, Requiring EEG for Accurate Diagnosis Diagnostic challenges can lead to Seizures are the most common under- and over-treatment neurological emergency in newborns up to Patient Population Prevalence of Seizures3,4 90% of neonatal seizures are non-convuls
Slide 20: Neonatal Seizures Require Urgent Diagnosis and Management
Neonatal Seizures Require Urgent Diagnosis and Management 1 hour in seizure is associated with Just 1 hour delay to treat seizure may lead to language impairment and cognitive deterioration1 higher seizure burden3 Predicted Language Score at 18 Months (Bayley-III) Median Seizure Burden 80 100 trend
Slide 21: Business Model: Two Sources of Recurring Revenue
Business Model: Two Sources of Recurring Revenue ~75% Product Recurring (single-patient disposable) ~25% Subscription Revenue (SaaS + loaned capital) + + Single-Use Headband Disposable AI Algorithm Recorder Portal SaaS Capital SaaS 21 CAUTION: Device does not substitute for EEG review by a qualified
Slide 22: Rapid Revenue Growth & Projectable Business Model
Rapid Revenue Growth & Projectable Business Model Quarterly Revenue ($ in million) $28.1 $26.5 $24.8 $22.6 $20.5 $21.2 $18.5 $17.2 $15.3 $14.4 $13.1 $10.9 $11.6 $9.5 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 22
Slide 23: Significant Opportunity For Continued Growth Within Core Seizure Market
Significant Opportunity For Continued Growth Within Core Seizure Market <4% of addressable 12% hospital penetration x 30% within existing accounts Market1 Ceribell is currently active in only Ceribell’s top customers use 712 out of roughly 6,000 hospitals approximately 3x the number of providing acu
Slide 24: 2026 Commercial Growth Drivers in Core Seizure Market
2026 Commercial Growth Drivers in Core Seizure Market Account Acquisition Drive Utilization in Existing Accounts • Execute on proven account acquisition strategy • Expand to new departments, EDs, ICUs • Drive productivity of recently expanded commercial • Train more providers in all shifts infrastru
Slide 25: Two-Pronged Platform Expansion Strategy
Two-Pronged Platform Expansion Strategy Algorithm Development Hardware Enhancements • Develop novel algorithms to support • Provide comprehensiveness of clinical expansion to new patient conventional EEG and speed of point-of- populations, and enhance seizure care EEG management offering • Launching
Slide 26: Ceribell's Three Growth Horizons
Ceribell’s Three Growth Horizons LONGER TERM NEAR TERM Develop Solutions for Use Beyond the NOW Make EEG a New Vital Sign Acute Care Setting In Acute Care New Clinical Settings Seizure Detection Indication Expansion in ICU in the Acute Care Setting and ED (Delirium, LVO Stroke) Biomarkers for Non-Ac
Slide 27: Ceribell's Goal: Make EEG A New Vital Sign
Ceribell’s Goal: Make EEG A New Vital Sign Stroke Seizure Delirium Other 27
Slide 28: Moving Beyond Seizure in the Acute Care Setting
Moving Beyond Seizure in the Acute Care Setting Received FDA Clearance: Received NTAP Favorable Delirium Algorithm Final Rule from CMS in August 2026 for delirium monitoring solution Activated First Pilot Sites Delirium Up to $2,171 per patient2 Targeting commercial launch Effective October 1, 2026
Slide 29: Delirium Represents a Significant Unmet Need
Delirium Represents a Significant Unmet Need Delirium, defined as an acute change in attention and awareness, is often called “acute brain failure” High Prevalence Poor Clinical Outcomes Unmet Need • 3+ million patients in the US1-4 • 1 ICU delirium day associated • Current diagnosis tool (CAM- with
Slide 30: Delirium & Seizure: A Hidden Clinical Overlap
Delirium & Seizure: A Hidden Clinical Overlap Seizure 48% of ICU seizure patients experience delirium1 Similar presentation... Delirium and Seizure Very different treatment approaches are Highly Interrelated 42% of ICU delirium patients have epileptiform abnormality2 Delirium 1. Frei A.I., et al. (2
Slide 31: Pipeline Programs Significantly Expand Ceribell's TAM
Pipeline Programs Significantly Expand Ceribell’s TAM Expanding to $3.5B >$3.5B Potential Market Opportunity1 TBD (U.S. Only) $3.5B LVO Stroke + Potential Other New Indications >$1B $2.5B ICU Delirium Expansion2 ~$400M Pediatric & Neonate Expansion <4% >$2B Adult Seizure Market 2025 2026 2027 Beyond
Slide 32: The First and Only
The First and Only Status Epilepticus Seizure Detection Algorithm Seizure Detection Algorithm FDA Breakthrough and CMS NTAP for Preterm Neonates for Ages 1+ Epileptiform Abnormality FedRAMP® High Delirium Detection Algorithm Pattern Detection Algorithm Authorization FDA Breakthrough and Cleared FDA
Slide 33: Clarity When It's Critical
ceribell Clarity When It’s Critical